The Deal
Saturday, November 21, 
5:08 pm

Entries tagged "Eli Lilly"

Is Eli Lilly the next pharma to be swallowed?

As consolidation in the pharma business continues, Eli Lilly could find itself becoming a target.


Fitch: ImClone an expensive pill for Lilly

Pharmaceutical company Eli Lilly and Co. made its biggest acquisition ever with its $6.5 billion cash deal to acquire biotech company ImClone Systems Inc. on Monday. But credit rating agency Fitch Ratings feels Eli Lilly is taking a risk that may warrant a possible credit rating downgrade....


Eli Lilly buys ImClone for $6.5B

Add another notch to Carl Ichan's belt. Eli Lilly and Co. will acquire ImClone Systems Inc. for $70 per share or about $6.5 billion. The deal was announced after ImClone rejected a sweetened bid from Bristol-Myers Squibb Co. Bristol first offered $60 a share July 31, then $62 and then threatened to go hostile last week. Bristol, which holds a 17% stake, wanted buy the rest of the shares in the company. ...


Bristol-Myers could make ImClone a hard pill to swallow

So Carl Icahn wasn't bluffing. Eli Lilly and Co. is apparently the mystery bidder for ImClone Systems Inc., and the company is in talks to acquire the New York-based biotech company for $6.1 billion, according to a report by The Wall Street Journal. ...


Rabble Babble: ImClone's mystery bidder to reveal itself this week

ImClone Systems Inc. said a mystery bidder, which has tentatively offered a bid of $70 a share or $6.1 billion, has informed the company that it will either make a formal bid or withdraw from talks by the end of the day on Wednesday.  ...



Top tags

You have executed a tag search on Dealscape. On the left,you will find a comprehensive list of stories tagged "Eli Lilly." Below are the most-popular tags for Dealscape. On the right of the page you will find a search box to dig deeper into our content.
The Deal Pipeline

Deal Video


Inside The Deal: Avaya Inc.'s Mohamad Ali on the company's next target.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

Managing your shareholder base

Growth companies and their PE sponsors should be wary of the pitfalls that arise when they layer on tiers of preferred stock.


Industry Insight

Easing the stress of distressed M&A

Corporate buyers face numerous complexities when trying to identify the right moment to purchase a distressed asset.


Editor's Note

Editor's letter: Nov. 16, 2009

Beneath the veneer of Wall Streeters beats the same heart, stirred by the same determinants of behavior.



©Copyright 2008, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.